Vivus (VVUS) - Get Report rose 11% Monday after the drug company said obese patients treated in a study with its Qnexa compound lost more weight than those taking a placebo.

The Mountain View, Calif., company said significant reductions were also seen in lipid levels.

"Qnexa demonstrated significant weight loss and reduction in waist circumference in this study, coupled with excellent tolerability and a positive impact on certain factors pertaining to metabolic syndrome in obese patients," Vivus said. "This is the first time the Qnexa Phase 2 data has been presented in a medical forum and represents the beginning of our education process with practicing physicians on the potential of Qnexa."

Shares rose 40 cents to $3.97.